Patkar Shraddha, Kattepur Abhay K, Khanna Nehal, Bajpai Jyoti
Department of Gastrointestinal Oncology, Hepatobiliary Services, Tata Memorial Centre and HBNI, Dr Ernst Borges Marg, Parel, Mumbai 400012 India.
Department of Surgical Oncology, Sri Devaraj Urs Academy of Higher Education and Research, Tamaka, Kolar, Karnataka India.
Indian J Surg Oncol. 2022 Sep;13(3):542-558. doi: 10.1007/s13193-022-01520-y. Epub 2022 Feb 21.
Retroperitoneal sarcomas are heterogeneous tumours with variable disease biology and outcomes. The prognosis is primarily related to tumour histology and grade as well as the ability to achieve margin negative resection. Surgery involves compartment or contiguous organ resection to achieve the above goal. Careful utilization of neoadjuvant and adjuvant strategies like radiotherapy and/or chemotherapy can lead to improvement in margin status, thereby contributing to better local control and possibly reducing systemic dissemination. Use of targeted therapies has paved newer pathways of treatment integration centred on molecular and genetic targets. The aim of this review is to update the reader on all aspects of retroperitoneal sarcoma management including emphasis on pertinent and landmark trials in this regard.
腹膜后肉瘤是具有可变疾病生物学特性和预后的异质性肿瘤。预后主要与肿瘤组织学、分级以及实现切缘阴性切除的能力有关。手术包括进行间隔或相邻器官切除以实现上述目标。谨慎使用放疗和/或化疗等新辅助和辅助策略可改善切缘情况,从而有助于更好地进行局部控制并可能减少全身播散。靶向治疗的应用开辟了以分子和基因靶点为中心的更新的治疗整合途径。本综述的目的是向读者介绍腹膜后肉瘤管理的各个方面,包括强调这方面相关的标志性试验。